|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  |  | | --- | --- | | |  | | --- | |  | | | |  | | --- | |  | | PSNC Newsletter | | Tuesday 11th April 2023 | | |  | | |  |  |  | | --- | --- | --- | |  |  |  | |  | This newsletter from PSNC is sent on Mondays, Wednesdays and Fridays. It contains important information for those that work in the community pharmacy sector. In this update: Newsletters schedule; HRT PPC support from PSNC; EPS outcomes and trackability survey; Serious Shortage Protocol updates.PSNC newsletter schedule this week Due to the Easter bank holidays, the PSNC newsletter timetable is different this week. Please note, there will not be a newsletter sent out tomorrow and the next newsletter is scheduled for **Friday 14th April**.  For the week commencing 17th April, the usual PSNC newsletter schedule (i.e. Monday, Wednesday, Friday) will resume. Reminder: HRT PPC guidance and support The Government introduced a new Prescription Prepayment Certificate (PPC) for hormone replacement therapy (HRT) products this month, and PSNC has recently published guidance and FAQs to help pharmacy teams to implement this new policy.  Whilst pharmacy teams may have read the guidance from Department of Health and Social Care (DHSC), PSNC's briefing contains supplementary information and a comprehensive set of FAQs based on our understanding of this policy from discussions with DHSC. It also contains a number of illustrative diagrams and flowcharts to help clarify the procedures.  [**Read the PSNC briefing**](https://psnc.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=e4637d3ccc&e=d19e9fd41c)  Additionally, a number of resources have also been published to help explain the new HRT PPC to patients and the general public.  [**View the patient materials**](https://psnc.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=c4eab258c1&e=d19e9fd41c) Chance to share your views on EPS outcomes PSNC, working with Kingston University and the Community Pharmacy IT Group (CP ITG), has launched a short survey to gather feedback about EPS Paperless, Outcomes and Trackability.  The short survey takes 5-10 minutes to complete. If you are able to spare a little time, your responses will be used to help shape the EPS priorities of the CP ITG and system suppliers.  [**Please complete the survey here**](https://psnc.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=f517405bc0&e=d19e9fd41c) SSP notices **Two SSPs issued for Clarithromycin oral suspensions** In response to a significant ongoing disruption to the supply of Clarithromycin 125mg/5ml and 250mg/5ml oral suspension, two Serious Shortage Protocols (SSPs) have been issued by DHSC.  Effective from 6 April 2023, SSP053 and SSP054 provide for the supply of a different strength or formulation to that originally prescribed. [**Learn more**](https://psnc.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=29f3f5d2cc&e=d19e9fd41c)  **SSP032 extended** Due to ongoing supply disruption, DHSC has further extended the SSP for Lipitor® 10mg chewable tablets to 28 April 2023. [**Learn more**](https://psnc.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=83c62bc6af&e=d19e9fd41c) |  | |  |  |  | | |
| |  |  |  | | --- | --- | --- | | |  | | --- | | Pharmaceutical Services Negotiating Committee      14 Hosier Lane, London, EC1A 9LQ Tel: 0203 1220 810 | Email: [**info@psnc.org.uk**](mailto:info@psnc.org.uk) | |  | | |

